Acelrx reports second quarter 2023 financial results and provides corporate update

Capital raise closed in july, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available acelrx awaits response to emergency use authorization (eua) of niyad™ submitted to the fda in april; registrational study set to initiate in q4 2023 proforma $17.4 million in cash as of june 30, 2023, including gross proceeds from financing closed in july 2023 senior debt with oxford fully repaid in q2 2023 webcast and conference call to be held today at 4:30 p.m. edt san mateo, calif.
ACRX Ratings Summary
ACRX Quant Ranking